Company intelligence / Profile preview

U.P. Oncolytics

Calgary, Alberta, Canadauponc.com ↗

Ownership: Private
Employees: ~29
Development stage: Preclinical

Overview

Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. Recent data from ASCO GI 2025 showed enhanced responses in anal cancer patients receiving pelareorep with atezolizumab compared to historical checkpoint inhibitor data. In pancreatic cancer, pelareorep demonstrated favorable safety when combined with modified FOLFIRINOX, with or without atezolizumab. The company is preparing for registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.

Therapeutic areas: Oncology
Modalities: ImmunotherapyOncolytic virus therapyImmuno-oncolytic virus (IOV)
Industry: Biotech

Partnerships

Academic and pharmaceutical collaborators (specific names not provided in search results)

Beyond the preview

Go deeper on U.P. Oncolytics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on U.P. Oncolytics.

Explore the full profile